DA Davidson Maintains Neutral on Medifast, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser has maintained a Neutral rating on Medifast (NYSE:MED) and raised the price target from $75 to $93.
July 31, 2023 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
DA Davidson has maintained a Neutral rating on Medifast and raised the price target from $75 to $93. This could potentially influence investor sentiment.
The news is directly about Medifast and is likely to influence investor sentiment. The raised price target indicates a positive outlook, but the Neutral rating suggests that the stock is fairly valued at the moment. Therefore, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100